德国生物技术公司需获批抗癌疗法,此前16名患者的早期数据显示细胞治疗对葡萄膜黑色素瘤有效
STAT+: A German biotech has big ambitions in cancer. Now it needs to get a medicine approved
一家德国生物技术公司旨在推动其抗癌疗法获批,该疗法在16名葡萄膜黑色素瘤患者的I期试验中显示肿瘤缩小。这些数据虽属初步结果,但提示该细胞疗法可能解锁免疫疗法在胰腺癌和卵巢癌等其他癌症中的潜力。
Presidential sessions at top cancer meetings typically feature practice-changing clinical trials, detailed in front of thousands of global experts packed into rooms so cavernous they merit their own ZIP codes. But last year, at the most important European oncology conference, one slot was reserved for a presentation of early results from a German biotech’s study of just 16 patients.
The primetime billing was no accident. The Phase 1 data, as oncologist Sapna Patel explained, showed that every one of the patients, all of whom had a rare eye cancer called uveal melanoma, saw their tumors shrink after receiving an experimental cell therapy — a remarkable, if preliminary, outcome. What was more, the data suggested that going after the therapy’s bull’s-eye might unlock the power of immunotherapy in other, more common cancers that had stubbornly rebuffed such efforts, like pancreatic and ovarian tumors.
“This can be taken forward in other areas of oncology,” Patel told the conference.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT 主站 · statnews.com